Publisher's Synopsis
Drugs in Context is an independent, peer reviewed and practice orientated review of all the significant data on a specific drug, placed in the context of the disease and clinical practice setting. Pimecrolimus Editorial: "The prevalence of atopy has risen relentiessly so that by the age of 7 years, 15% of children in the developed world can expect to have had at least one episode of eczema." Disease Overview: "Although there is usually a strong familial history of atopic disease, environmental factors, including socioeconomic status, family, size, exposure to allergens and early childhood infection contribute heavily to disease manifestation." Drug Review: "No skin atrophogenic potential was observed with pimecrolimus, in contrast with the corticosteroids which were shown to cause skin atrophy and altered skin texture." Improving Practice: "Treating atopic dermatitis earlier in life and more effectively holds the intriguing possibility that fewer children would go on to develop asthma and allergic rhinitis, a frequently observed phenomenon called the atopic march."
